BMY.SW stock closed at CHF 42.54 on the SIX market on 27 Feb 2026, down 4.40% from the previous close. The drop left volume light at 500.00 shares but pushed the share price below the 50‑day average of CHF 43.75, setting a short‑term oversold bounce condition. Traders watching an oversold bounce will compare the quick pullback to earnings, debt metrics and cash flow to judge a recovery. This note uses on‑chain metrics and Meyka AI powered market analysis to map risk and a near‑term price path for investors on the Swiss exchange.

Price action and setup for BMY.SW stock

BMY.SW stock closed CHF 42.54, a -4.40% intraday move from the prior close of CHF 44.50. The day high and day low matched at CHF 42.54, showing a single print session and thin liquidity with volume 500.00 shares. The relative volume of 22.73 signals a concentrated trade window, increasing short‑term volatility.

Fundamentals and valuation for BMY.SW stock

Bristol‑Myers Squibb (BMY.SW) trades with a trailing EPS of 2.66 and a PE of 15.99, below the Healthcare sector average PE of 35.33. Market cap stands at CHF 70,703,584,454.00, with debt to equity at 2.75, highlighting leverage pressure versus peers. Free cash flow yield of 23.36% and dividend yield of 3.50% support an income case despite elevated leverage.

Technicals and oversold bounce signals for BMY.SW stock

Technicals show a sharp short‑term momentum shift. MACD histogram is -0.07 and ADX reads 100.00, indicating a strong directional move. Price sits under the 50‑day and 200‑day averages (CHF 43.75). Given the stretched intraday drop and oversold momentum, a measured bounce toward CHF 43.75 is a plausible short‑term target for traders.

Meyka AI grade and forecast for BMY.SW stock

Meyka AI rates BMY.SW with a score out of 100. Meyka AI rates BMY.SW with a score of 73.50 out of 100 (Grade: B+, Suggestion: BUY). This grade factors S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a one‑year level at CHF 39.34, implying -7.53% versus the current price of CHF 42.54. Forecasts are model‑based projections and not guarantees.

Risks, catalysts and sector context for BMY.SW stock

Key near‑term risks include high leverage, litigation headlines, and weaker drug sales. Catalysts that could trigger an oversold bounce include a positive earnings update, new label approvals, or stabilization in U.S. revenue. Healthcare sector performance has outpaced broader markets year to date, so sector tailwinds could support a recovery in BMY.SW stock.

Trading considerations and strategy for BMY.SW stock

For an oversold bounce strategy, use tight risk controls. Consider scalps or small position adds near support at CHF 42.54 with stop losses sized to risk tolerance. Watch upcoming earnings on 30 Apr 2026 and monitor liquidity on SIX. Link to the Meyka stock page for live indicators and alerts: Meyka BMY.SW page.

Final Thoughts

BMY.SW stock shows a clear oversold bounce setup after a -4.40% drop to CHF 42.54 on SIX. Fundamentals remain mixed: attractive cash flow yields and a 3.50% dividend versus heavy leverage at 2.75 debt to equity. Meyka AI’s model projects a one‑year level of CHF 39.34, implying -7.53% from the current price, which signals modest downside in the medium term. Traders targeting an oversold bounce should prioritise tight stops and event risk ahead of the 30 Apr 2026 earnings announcement. Use the lower‑risk approach of small entries and quick profit targets toward the 50‑day mean (CHF 43.75). Meyka AI provides the data and alerts to track this setup in real time, but forecasts are model‑based and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.